• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结构解析 Toll 样受体干扰素-β相关衔接蛋白二聚体界面有害突变的作用。

Structural insights into the role of deleterious mutations at the dimeric interface of Toll-like receptor interferon-β related adaptor protein.

机构信息

National Centre for Biological Sciences (TIFR), GKVK Campus, Bangalore, Karnataka, India.

Molecular Biophysics Unit, Indian Institute of Science, Bangalore, Karnataka, India.

出版信息

Proteins. 2024 Oct;92(10):1242-1258. doi: 10.1002/prot.26707. Epub 2024 May 30.

DOI:10.1002/prot.26707
PMID:38814166
Abstract

Toll-like receptors (TLRs) are major players in the innate immune system-recognizing pathogens and differentiating self/non-self components of immunity. These proteins are present either on the plasma membrane or endosome and recognize pathogens at their extracellular domains. They are characterized by a single transmembrane helix and an intracellular toll-interleukin-1 receptor (TIR) domain. Few TIRs directly invoke downstream signaling, while others require other TIR domains of adaptors like TIR domain-containing adaptor-inducing interferon-β (TRIF) and TRIF-related adaptor molecule (TRAM). On recognizing pathogenic lipopolysaccharides, TLR4 dimerises and interacts with the intracellular TRAM dimer through the TIR domain to recruit a downstream signaling adaptor (TRIF). We have performed an in-depth study of the structural effect of two mutations (P116H and C117H) at the dimeric interface of the adaptor TRAM, which are known to abrogate downstream signaling. We modeled the structure and performed molecular dynamics studies in order to decipher the structural basis of this effect. We observed that these mutations led to an increased radius of gyration of the complex and resulted in several changes to the interaction energy values when compared against the wild type (WT) and positive control mutants. We identified highly interacting residues as hubs in the WT dimer, and a few such hubs that were lost in the mutant dimers. Changes in the protein residue path, hampering the information flow between the crucial A86/E87/D88/D89 and T155/S156 sites, were observed for the mutants. Overall, we show that such residue changes can have subtle but long-distance effects, impacting the signaling path allosterically.

摘要

toll 样受体(TLRs)是先天免疫系统中的主要参与者-识别病原体并区分自身/非自身免疫成分。这些蛋白存在于质膜或内体上,在外周域识别病原体。它们的特征是单一跨膜螺旋和细胞内 toll-白细胞介素-1 受体(TIR)结构域。少数 TIR 直接引发下游信号,而其他则需要其他适配器的 TIR 结构域,如 TIR 结构域包含适配器诱导干扰素-β(TRIF)和 TRIF 相关适配器分子(TRAM)。在识别致病脂多糖时,TLR4 二聚化并通过 TIR 结构域与细胞内 TRAM 二聚体相互作用,招募下游信号适配器(TRIF)。我们对适配器 TRAM 二聚体界面上两个突变(P116H 和 C117H)的结构效应进行了深入研究,已知这两个突变会阻断下游信号。我们对结构进行建模并进行分子动力学研究,以破译这种效应的结构基础。我们观察到这些突变导致复合物的旋转半径增大,并且与野生型(WT)和阳性对照突变体相比,相互作用能值发生了几个变化。我们确定了高相互作用残基作为 WT 二聚体中的枢纽,并且在突变体二聚体中丢失了几个这样的枢纽。在突变体中观察到蛋白质残基路径的变化,阻碍了关键 A86/E87/D88/D89 和 T155/S156 位点之间的信息流。总的来说,我们表明这种残基变化可能具有微妙但远距离的影响,变构地影响信号通路。

相似文献

1
Structural insights into the role of deleterious mutations at the dimeric interface of Toll-like receptor interferon-β related adaptor protein.结构解析 Toll 样受体干扰素-β相关衔接蛋白二聚体界面有害突变的作用。
Proteins. 2024 Oct;92(10):1242-1258. doi: 10.1002/prot.26707. Epub 2024 May 30.
2
Functional interfaces between TICAM-2/TRAM and TICAM-1/TRIF in TLR4 signaling.TICAM-2/TRAM与TICAM-1/TRIF在TLR4信号传导中的功能接口。
Biochem Soc Trans. 2017 Aug 15;45(4):929-935. doi: 10.1042/BST20160259. Epub 2017 Jun 19.
3
A genome-wide search of Toll/Interleukin-1 receptor (TIR) domain-containing adapter molecule (TICAM) and their evolutionary divergence from other TIR domain containing proteins.全基因组范围内 Toll/白细胞介素-1 受体(TIR)结构域包含衔接分子(TICAM)及其与其他 TIR 结构域蛋白的进化分歧。
Biol Direct. 2022 Sep 2;17(1):24. doi: 10.1186/s13062-022-00335-9.
4
Investigating the effect of key mutations on the conformational dynamics of toll-like receptor dimers through molecular dynamics simulations and protein structure networks.通过分子动力学模拟和蛋白质结构网络研究关键突变对Toll样受体二聚体构象动力学的影响。
Proteins. 2018 Apr;86(4):475-490. doi: 10.1002/prot.25467. Epub 2018 Feb 9.
5
Integrative modelling of TIR domain-containing adaptor molecule inducing interferon-β (TRIF) provides insights into its autoinhibited state.含TIR结构域的衔接蛋白分子诱导干扰素-β(TRIF)的整合模型揭示了其自身抑制状态。
Biol Direct. 2017 Apr 20;12(1):9. doi: 10.1186/s13062-017-0179-0.
6
A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling.衔接蛋白TRAM和TRIF在 Toll样受体2信号传导中的作用。
J Biol Chem. 2015 Feb 6;290(6):3209-22. doi: 10.1074/jbc.M114.593426. Epub 2014 Dec 11.
7
Structures and interface mapping of the TIR domain-containing adaptor molecules involved in interferon signaling.干扰素信号转导相关含 TIR 结构域衔接分子的结构与界面映射。
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19908-13. doi: 10.1073/pnas.1222811110. Epub 2013 Nov 19.
8
Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain.TLR 衔接子 TRIF 招募到 TLR4 信号复合物是由 TRIF TIR 结构域的第二个螺旋区介导的。
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19036-41. doi: 10.1073/pnas.1313575110. Epub 2013 Nov 5.
9
Evolution of the TIR domain-containing adaptors in humans: swinging between constraint and adaptation.人类 TIR 结构域包含衔接蛋白的进化:在约束和适应之间摇摆。
Mol Biol Evol. 2011 Nov;28(11):3087-97. doi: 10.1093/molbev/msr137. Epub 2011 Jun 9.
10
Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis.造血细胞中的 Toll 样受体 3 和 4 通过 TRIF 和 TRAM 接头的信号转导促进动脉粥样硬化。
Cardiovasc Res. 2013 Jul 15;99(2):364-73. doi: 10.1093/cvr/cvt033. Epub 2013 Feb 14.

引用本文的文献

1
Pattern recognition receptors: function, regulation and therapeutic potential.模式识别受体:功能、调控及治疗潜力
Signal Transduct Target Ther. 2025 Jul 11;10(1):216. doi: 10.1038/s41392-025-02264-1.
2
Toll-like receptor 4 pathway evolutionary trajectory and functional emergence.Toll样受体4通路的进化轨迹与功能出现
Front Immunol. 2025 Jan 20;15:1494017. doi: 10.3389/fimmu.2024.1494017. eCollection 2024.